New hope for endometriosis pain: hormone pill targets inflammation
NCT ID NCT07100782
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 36 times
Summary
This study tests whether a hormone-suppressing drug called Relugolix CT (Myfembree) can reduce pelvic pain, inflammation, and pain sensitivity in women with endometriosis. Researchers will measure changes in blood markers and brain scans in 130 participants over several months. The goal is to understand how lowering estrogen affects pain pathways.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Relugolix combination therapy (Relugolix, estradiol, norethindrone acetate) - a hormone-suppressing drug
What this could lead to
If successful, this could show that hormone suppression reduces inflammation and pain sensitivity, pointing toward a better treatment for endometriosis-related pelvic pain.
What could go wrong
This is a Phase 3 trial, but it's still relatively small (130 participants) and focuses on biological markers, not just pain relief. Results may not apply to all patients, and hormone suppression can cause side effects like hot flashes or bone density loss.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.